Assessment of neuronal and glial serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease: the MULTIMOGAD study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marignier Romain, Villacieros-Álvarez Javier, Espejo Carmen, Arrambide Georgin, Fissolo Nicolás, Gutiérrez Lucía, Dinoto Alessandro, Mulero Patricia, Rubio-Flores Laura, Nieto Pablo, Alcalá Carmen, Meca-Lallana Jose E, Martínez-Garcia Pedro, Millán Jorge, Bernard-Valnet Raphaël, González Inés, Orvíz García Aida, Tellez Raquel, Navarro Laura, Presas-Rodríguez Silvia, Romero-Pinel Lucía, Martínez-Yélamos Sergio, Cuello Juan Pablo, Alonso Torres Ana Maria, Piñar Raquel, Álvarez Bravo Gary, Benyahya Lakhdar, Trouillet-Assant Sophie, Dyon-Tafani Virginie, Froment Tilikete Caroline, Ruet Aurelie, Bourre Bertrand, Deschamps Romain, Papeix Caroline, Maillart Elisabeth, Kerschen Philippe, Ayrignac Xavier, Rovira Alex, Auger Cristina, Audoin Bertrand, Montalban Xavier, Tintore Mar, Mariotto Sara, Cobo-Calvo Alvaro
Аннотация
METHODS: Retrospective study of adult MOGAD patients with serum samples collected at baseline (≤3 months from disease onset) and follow-up (>6 months from baseline sample). sNfL and sGFAP were analysed using Simoa HD-1, and values were compared across time-points. The association between biomarkers and clinical variables and their predictive value for disability and relapses were analysed.
RESULTS: Eighty-nine MOGAD patients were included. Baseline sNfL and sGFAP values were high at baseline and decreased over time (p<0.001, p=0.027, respectively). sNfL and sGFAP values were associated with Expanded Disability Status Scale (EDSS) at attacks (β 0.15 (0.06; 0.25), p=0.002; β 0.14 (0.07; 0.21), p<0.001, respectively) and were lower in optic neuritis presentations (β -0.69 (-1.18; -0.19), p=0.007; β -0.42 (-0.76; -0.08), p=0.016). Biomarker deltas[Δ] (baseline values - second samples values) were associated with ΔEDSS (initial EDSS - final EDSS) (ΔsNfL β 0.52 (0.01; 1.04), p=0.046; ΔsGFAP β 1.07 (0.38; 1.75), p=0.003). Finally, sNfL values independently predicted the risk of relapses (HR 2.06 (1.41; 3.01), p<0.001).
CONCLUSIONS: Our results on sNfL and sGFAP suggest initial neuro-axonal and astrocytic damage in MOGAD and the utility of these biomarkers at onset and follow-up in predicting clinical recovery and relapses.